Private equity firm TA Associates has mandated Jefferies as sell-side advisor to assist with the stake sale of Mumbai-based dietary supplements and beverage producer OmniActive Health Technologies, said two sources familiar with the situation.

The sale process is in the preliminary stage, but will likely be delayed as the ongoing tariff war could affect valuation, said the first source.

It will mostly be a secondary sale, said the second source, adding that the company may command up to USD 800m in valuation.

The sale would likely draw interest from private equity firms and large strategics, the first source added.

OmniActive could be valued at up to USD 1bn for this sale, as reported in March 2025. In 2021, TA Associates acquired a majority stake of around 60% in the company from Everstone Capital for USD 150m, as reported at the time. IIFL Asset Management also acquired a minority stake in the target, as reported in 2022.

Founded in 2005, OmniActive’s product portfolio consists of scientifically validated, IP-protected Specialty Actives and an extensive portfolio of natural Botanical Actives for global customers in the dietary supplement, functional food, and beverage markets, according to a company press release. It has offices in Mumbai and Bridgewater, New Jersey.

OmniActive Health Technologies acquired Mumbai-based supplier of active botanical ingredients ENovate Biolife in November 2024, as reported. Terms of the deal were not disclosed.

OmniActive clocked INR 8.43bn (USD 98.6m) in revenues in FY25, according to the second source.

TA Associates, Jefferies, and OmniActive did not respond to requests seeking comment.